Trial Profile
A Phase 1/2, Randomized, Placebo-Controlled Clinical Study to Investigate the Clinical Safety and Immunogenicity of a Vaccine Candidate DPX-COVID-19
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2021
Price :
$35
*
At a glance
- Drugs DPX COVID-19 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors IMV
- 17 Mar 2021 According to an IMV media release, it intends to submit preclinical study results supporting the Phase 1/2 clinical trial in a peer-reviewed scientific journal in Q2 2021
- 12 Nov 2020 According to an IMV media release, preliminary results are expected in Q1 2021.
- 08 Oct 2020 According to an IMV media release, the trial is expected to be initiated before the end of 2020.